Helus Pharma advances groundbreaking trials for depression and anxiety disorders by 2026
Cybin, now operating under Helus Pharma, has secured funding to push forward two key clinical programmes. The company is focusing on treatments for treatment-resistant depression and generalized anxiety disorder. With regulatory approvals in place, major trial results are expected in 2026.
The company’s financial position looks strong, with around $248 million in liquid assets following an October 2025 capital raise. This funding is projected to cover operations for the next 21 to 22 months.
Two programmes are advancing simultaneously. CYB003, designed for treatment-resistant depression, will enter its first pivotal Phase 3 trial in late 2026. A second Phase 3 study is also planned, following recent regulatory green lights in multiple countries. Meanwhile, CYB004, targeting generalized anxiety disorder, is in Phase 2 testing, with topline data due in early 2026.
Market analysts appear optimistic about Cybin’s prospects. Three have rated the stock as a 'Strong Buy', setting an average price target of $89. The shares, last traded at CAD 10.60, have shown a steady recovery over the past month.
The upcoming clinical data will shape Cybin’s future trajectory. Results from both CYB003 and CYB004 trials in 2026 will determine the next steps for these treatments. With sufficient funding and regulatory approvals secured, the company is positioned to move forward with its development plans.
